Epidermal growth factor enhances MPC-83 pancreatic cancer cell migration through the upregulation of aquaporin 3.
暂无分享,去创建一个
[1] B. Carr,et al. Cell membrane and cytoplasmic epidermal growth factor receptor expression in pancreatic ductal adenocarcinoma , 2012, Medical Oncology.
[2] D. Ribatti,et al. Role of aquaporins in cell migration and edema formation in human brain tumors. , 2011, Experimental cell research.
[3] Yi-Song Wang,et al. Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors. , 2011, Cancer treatment reviews.
[4] Stephen L. Abrams,et al. Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy , 2011, Leukemia.
[5] A. Bardelli,et al. Integrated molecular dissection of the epidermal growth factor receptor (EFGR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer , 2010, Targeted Oncology.
[6] C. Campen,et al. Anti-EGFR-Targeted Therapy for Esophageal and Gastric Cancers: An Evolving Concept , 2009, Journal of oncology.
[7] A. Engel,et al. The AQP structure and functional implications. , 2009, Handbook of experimental pharmacology.
[8] M. Caruso,et al. EGFR-targeted therapy in colorectal cancer: does immunohistochemistry deserve a role in predicting the response to cetuximab? , 2008, Current opinion in molecular therapeutics.
[9] M. Papadopoulos,et al. Aquaporins—new players in cancer biology , 2008, Journal of Molecular Medicine.
[10] M. Papadopoulos,et al. Aquaporins and cell migration , 2008, Pflügers Archiv - European Journal of Physiology.
[11] D. Arpin,et al. [Tyrosine kinase inhibitors in the management of non-small cell lung cancer]. , 2007, Revue des maladies respiratoires.
[12] Sugunavathi Sepramaniam,et al. Aquaporins: a promising target for drug development , 2006, Expert opinion on therapeutic targets.